Is the compounded formulation more effective than OTC minoxidil alone?

Adding a 5α-reductase inhibitor (topical finasteride) addresses a pathway minoxidil alone does not, the androgen-driven miniaturization. Combination formulations may provide superior density maintenance versus monotherapy in some studies, though large head-to-head RCTs of compounded fixed combinations are limited. 5 percent minoxidil is superior to 2 percent in direct-comparison trials.

Women of childbearing potential should avoid finasteride-containing formulations. Postmenopausal women with female pattern hair loss may be appropriate candidates for minoxidil-containing or carefully selected low-finasteride formulations under provider guidance.

What happens if I stop?

AGA is a progressive condition. Treatment maintains and may improve hair density, but does not cure the underlying genetic susceptibility. Gains typically reverse toward pre-treatment trajectory within 3 to 6 months of discontinuation.

Topical vs. oral finasteride, which is better?

Oral finasteride has the most robust long-term efficacy data. Topical finasteride offers substantially lower systemic exposure, which may reduce sexual side-effect risk while maintaining meaningful local DHT reduction. Choice depends on severity, patient preference, and tolerance.

Topical therapy

Hair Restoration Topical Compound, Minoxidil and Finasteride for Androgenetic Alopecia

A 503A pharmacy-compounded scalp formulation pairing minoxidil with topical finasteride. Component drugs are FDA-approved. The combination is compounded.

Book a Consultation Talk to a Provider

Editorial 4:5 still life: cream-stoneware dropper bottle on a sunlit linen surface, soft warm window light, calm aesthetic.

Androgenetic alopecia (AGA), pattern hair loss in men and women, is the most common cause of hair loss and one of the most well-studied. The individual ingredients in compounded hair restoration topicals (minoxidil and finasteride) are FDA-approved and supported by decades of clinical data. The compounded combination in a single topical vehicle is 503A pharmacy-prepared and not FDA-approved as a fixed-dose combination.

Genesis Longevity offers this compound as a physician-supervised treatment for appropriate candidates, with clear disclosure about what the formulation is and what the evidence shows.

What it is

About this therapy

Genesis Longevity's hair restoration topical is a 503A pharmacy-compounded scalp formulation typically containing:

Minoxidil 5 to 10 percent, the primary vasodilatory and follicle-stimulating agent.
Finasteride 0.1 to 0.25 percent (or dutasteride), a 5α-reductase inhibitor that reduces scalp DHT with substantially lower systemic absorption than oral finasteride.
Optional additions: latanoprost 0.004 to 0.1 percent, caffeine, biotin.

The combination addresses multiple AGA pathways simultaneously, follicle vasodilation (minoxidil) and androgen pathway inhibition (finasteride), while reducing the systemic side-effect profile associated with oral finasteride.

How it works

Mechanism of action

Minoxidil. Originally developed as an oral antihypertensive, minoxidil was found to have a hair-growth side effect that led to its reformulation as a topical agent. It acts as a potassium channel opener in follicular smooth muscle, vasodilating the follicular vasculature and delivering more oxygen and nutrients to hair follicles. It also prolongs the anagen (active growth) phase and reverses follicular miniaturization, the hallmark of AGA.

Topical finasteride. Finasteride is a 5α-reductase type II inhibitor. DHT (dihydrotestosterone), the androgen primarily responsible for follicular miniaturization in genetically susceptible individuals, is reduced at the follicle level (via topical application) with substantially lower plasma levels and systemic side-effect risk than oral use.

Latanoprost. A prostaglandin F2α analog that stimulates anagen entry and follicle growth. A 2012 RCT demonstrated increased hair density with topical latanoprost vs. placebo in AGA.

Caffeine and biotin. Adjunct ingredients with modest evidence at scalp-applied cosmetic concentrations.

Conditions and use cases

Where this therapy may fit

Male androgenetic alopecia, Norwood II to V. Strongest evidence base for both components.
Female pattern hair loss, Ludwig I to II, especially postmenopausal. Off-label for finasteride-containing formulations. Used with provider judgment.
Patients seeking systemic side-effect reduction. Topical route substantially lowers systemic finasteride exposure vs. oral.
Adjunct to PRP, microneedling, or laser hair therapy for enhanced maintenance.

Expected timeline

What to expect over a care cycle

Week 0 to 2
Initiation phase
Initial telogen effluvium (temporary shedding) is commonly reported in the first 2 to 8 weeks. This is expected and self-limiting.
Week 2 to 4
Application routine
1 mL applied to dry scalp once daily, typically in the evening. Air-dry 2 to 4 hours. Avoid washing for 4 hours after application.
Month 1 to 3
Stabilization
Visible stabilization of hair loss in months 3 to 6. New growth may begin to appear. Provider checks adherence and tolerability.
Month 3 to 6
Approach to peak efficacy
Most patients see maximum benefit at approximately 12 months of consistent use. Maintenance is required. Discontinuation reverses gains within 3 to 6 months.

Stacks that include this

Pairs with the Male Vitality stack

Male Vitality
Provider-led hormone therapy for men's wellness.
TRT or Enclomiphene (lab-guided)Optional: PT-141Optional: NAD+

Investment and access

How to access this therapy at Genesis

Genesis Longevity therapies are dispensed only after a complimentary consultation and Good Faith Exam. Schedule yours to receive a personalized plan.

Book a Consultation See the patient journey

Safety

Side effects and contraindications

Reported side effects

Minoxidil.

Scalp pruritus, dryness, contact dermatitis, particularly at higher concentrations (10 percent more than 5 percent).
Initial shedding during first weeks, normal and self-limiting.
Hypertrichosis (unwanted facial hair) if solution migrates beyond scalp. Limit application to scalp only.

Topical finasteride.

Sexual side effects, lower incidence than oral. Post-finasteride syndrome is debated in the literature.
Rare mood changes.

Latanoprost.

Eyelash hyperpigmentation or hypertrichosis if solution reaches eyes. Wash hands thoroughly.
Iris hyperpigmentation with chronic eye contact (rare and only relevant if eye exposure occurs).

Contraindications and patient selection

Absolute contraindications.

Women of childbearing potential. Finasteride (even topical) carries teratogenic risk for male fetus genital development. Reliable contraception or avoidance is required.
Active scalp infection or open scalp wounds.
Hypersensitivity to any component (minoxidil, finasteride, latanoprost, propylene glycol).

Relative, requiring discussion.

Men with PSA monitoring requirements. Discuss with prescribing provider and any urologist monitoring prostate health.
Women with hormone-sensitive conditions. Discuss finasteride appropriateness.
Patients considering pregnancy.

Frequently asked

Frequently asked questions

Sources

Citations & references

[1]US Pharmacist, Minoxidil 10 percent / finasteride 0.1 percent / biotin / caffeine compound formulation. Source
[2]Topical finasteride and minoxidil clinical evidence review. PMC10239632.
[3]Olsen EA et al. 5 percent topical minoxidil foam in men. PubMed 17761356.
[4]Latanoprost-finasteride-minoxidil compound pilot trial. PMC11588191.
[5]Topical AGA treatment options review. PMC9298335.
[6]American Academy of Dermatology, Diagnosing and treating hair loss. Source

Status & disclosures

FDA status: The compounded topical combination is a 503A preparation, not FDA-approved as a fixed combination. Component drugs (minoxidil 5 percent OTC, oral finasteride 1 mg) are individually FDA-approved. Topical finasteride is compounded and not FDA-approved as a topical drug.
503A compounding: Each Genesis compounded topical is prepared by a licensed 503A compounding pharmacy with a beyond-use date and dispensed with provider-specific instructions.
Female use: Use in women is off-label and dose-sensitive. Women of childbearing potential should not use finasteride-containing formulations.
PSA considerations: If concurrent oral finasteride is considered, PSA monitoring is required. Oral finasteride reduces PSA by approximately 50 percent.

Next step

Considering a compounded hair restoration topical?

Genesis providers walk through diagnosis, formulation choice, and tradeoffs at consultation.